1. GPCR/G Protein
  2. Guanylate Cyclase

Guanylate Cyclase

Guanylatecyclase (guanylylcyclase, GC) is a lyase enzyme. Guanylylcyclase is often part of the G protein signaling cascade that is activated by low intracellular calcium levels and inhibited by high intracellular calcium levels. In response to calcium levels, guanylylcyclase synthesizes cGMP from GTP. cGMP keeps cGMP-gated channels open, allowing for the entry of calcium into the cell. The guanylylcyclase activity is modulated by the calcium-binding guanylylcyclase activating proteins (GCAP1 and GCAP2). A key mechanism by which Ca2+ modulates phototransduction in rods involves the synthesis of cGMP by guanylylcyclase (GC), regulated by a pair of Ca2+-binding GuanylylCyclase Activating Proteins (GCAP1 and GCAP2).

The second messenger cyclic guanosine monophosphate (cGMP) is generated by the heterodimeric α/β-heme protein soluble guanylatecyclase (sGC) upon activation by its endogenous ligand nitric oxide (NO). NO binds to the reduced prosthetic heme group bound to the β subunit. cGMP is a key mediator of the cardiovascular system and its effects lead to vasodilation, inhibition of smooth muscle proliferation, blockade of leukocyte infiltration and inhibition of platelet aggregation. Impairment of the cytoprotective NO/sGC/cGMP-signalling pathway is associated with the development of serious cardiovascular diseases such as hypertension or heart failure.

Guanylate Cyclase Related Products (7):

Cat. No. Product Name Effect Purity
  • HY-14927
    Lificiguat Activator 99.19%
    Lificiguat binds to the β subunit of soluble guanylyl cyclase(sGC) with Kd of 0.6-1.1 μM in the presence of CO.
  • HY-14779
    Riociguat Activator 99.73%
    Riociguat is an oral stimulator of soluble guanylate cyclase (sGC), and used in the treatment of pulmonary hypertension.
  • HY-17584
    Linaclotide Agonist 98.96%
    Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
  • HY-14181
    Cinaciguat Activator 99.64%
    Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.
  • HY-12376
    BAY 41-2272 Activator 99.93%
    BAY 41-2272 is a soluble guanylate cyclases (sGC) activator.
  • HY-16774
    Vericiguat Activator >98.0%
    Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.
  • HY-14181A
    Cinaciguat hydrochloride Activator
    Cinaciguat hydrochloride is a potent soluble guanylate cyclase (GC) activator with EC50 of 15 nM in platelets.